When would you add daratumumab to a PI/IMiD/dex backbone for first-line treatment of transplant-eligible multiple myeloma?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • Hematology

Are the early results of CASSIOPEIA (Abst 8003) from ASCO 2019 practice changing? What about the GRIFFIN results in 2020?

Answer from: Medical Oncologist at Community Practice

Short answer - in patients with low risk disease.Long answer - CASSIOPEIA enrolled fit patients below 65 years of age with adequate kidney function (greater than or equal to 40 mL/min/1.73 m2) with predominantly stage 1 & 2 disease by the revised international staging system (91% in Dara-VTd, 90...

Comments

Medical Oncologist at Clinical Instructor
Thank you Dr. @Craig C. Hofmeister for your though...

Answer from: Medical Oncologist at Academic Institution

The only published phase 3 study currently using Daratumumab as part of front line regimen is in non-transplant newly diagnosed patients using Dara-VMd vs VMd. In transplant-eligible, the GRIFFIN study comparing Dara -VRD(velcade/revlimid/dex) versus VRD alone as induction in transplant-eligible new...

Related Questions